RDIF CEO Kirill Dmitriev said in a statement on Monday that Sputnik V pioneered the vaccine cocktail approach with two shots. The Gamaleya Center's testing has shown that this strategy is valid, as the virus-neutralizing activity against new, more hazardous and infectious strains remains higher than that of many other vaccinations.,basketball-ground-diagram-in-marathi
Gamaleya Research Institute studied the immunological response or "virus-neutralizing activity (VNA)" triggered by the Sputnik V vaccination, according to the approach provided by RDIF. Live viruses were used in the study, which RDIF claims "provides the most trustworthy data and is the gold standard." RDIF will continue to sponsor additional studies of Sputnik V's efficacy against new strains, as well as exploring options to collaborate with other leading vaccine companies in accordance with RDIF CEO Kirill Dmitriev.,vợt-tennis-prince-exo3
volleyball-coach-quotes,According to the RDIF, the Russian-made Sputnik V vaccine has been registered in 67 countries. The vaccine has been approved for emergency use in India and is currently being provided at a few private hospitals.
The data gathered during the vaccination of the population in a number of countries, including Mexico, Argentina, Serbia, Bahrain, Hungary, San-Marino, UAE, and others, shows that Sputnik V is one of the safest and most effective coronavirus vaccines. Russian health officials have received no reports of unusual blood-clotting disorders in persons who received the Sputnik V vaccination, unlike the Oxford-AstraZeneca and Johnson & Johnson vaccines.,does-pokerstars-have-an-app
(Inputs from ANI)